33 results about "C protein" patented technology

The invention discloses an indirect ELISA (enzyme-linked immuno sorbent assay) kit for detecting a haemophilus parasuis antibody. The kit consists of an ELISA coating plate with haemophilus parasuis cytolethal distending toxin)-C protein serving as a coating antigen, a to-be-detected sample dilution plate, a positive contrast serum, a negative contrast serum, 20-time concentrated washing liquid, a serum sample dilution solution, an enzyme-labeled antibody working solution, a developing solution and a terminating solution. A judgment standard is that if an S / P value is less than 0.200, a sample to be detected is negative; if the S / P value is greater than or equal to 0.200, the to-be-detected sample is positive; the S / P value is obtained according to a formula: S / P value=(the mean value of the to-be-detected sample OD450nm-the mean value of a negative contrast OD450nm) / (the mean value of a positive sample OD450nm-the mean value of the negative contrast OD450nm). Due to the specificity test, the sensitivity test, the repetitiveness test, the coincidence rate test, the test for comparing the kit disclosed by the invention with a kit on sale, the clinical application test and the like, the kit disclosed by the invention has the characteristics of high specificity, high sensitivity, high repetitiveness and the like and is high in coincidence rate to the same type of products on sale home and abroad; the indirect ELISA kit can be used for clinical large-scale detection and epidemiological investigation for the haemophilus parasuis antibodies.

The invention relates to reconstituted surfactants consisting of artificial phospholipids and peptides able to lower the air-liquid surface tension, more particularly to reconstituted surfactants comprising special phospholipid mixtures and artificial peptides which are analogues of the natural surfactant SP-C protein for the treatment of respiratory distress syndrome (RDS) and other diseases relating to pulmonary surfactant dysfunctions.

The present invention relates to polynucleotides encoding immunogenic HIV type C polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of HIV Type C proteins are also described.

The present invention relates to polynucleotides encoding immunogenic HIV type C polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of HIV Type C proteins are also described.

An isolated polypeptide comprising an amino acid sequence corresponding to the amino acid residues forming a full or partial alpha-helical domain, the hinge domain, the beta-triple spiral domain and afull or partial globular head domain of an avian reovirus sigma C protein, and lacking the amino acid sequence that is N-terminal to said alpha-helical domain is provided. Furthermore, a vaccine comprising, or a viral vector expressing, at least one of the isolated polypeptides of the present invention is provided.

Monoclonal antibodies, which can be produced in vitro, against cardiac epitopes of the human My-C are produced by generating myeloma cell clones that produce such specific antibodies having epitope specificity. These monoclonal antibodies allow, among other things, the creation of an enzyme-linked immunosorbent assay (ELISA) for the specific, cross-reactivity-free quantitative determination of My-C in serum, plasma, whole blood or other body fluid. Specifically, a hybridoma cell clone producing a monoclonal antibody that detects and binds a cardiac epitope in the My-C is produced, which has no cross-reactivity with respect to the myosin-binding proteins of the skeletal muscles. The hybridoma cell line can be obtained by fusing myeloma cells with spleen cells of a test animal, in particular a mouse, immunized against recombinant My-C. The invention furthermore relates to epitope-specific antibodies produced by the hybridoma cell line, and to the use thereof.

Methods and compositions for rapidly replacing cMyBP-C in sarcomeres featuring the creation of Spy-C mice, which are mice genetically engineered to express cMyBP-C with a protease recognition site and SpyTag peptide introduced into the cMyBP-C gene. In permeabilized myocytes from the Spy-C mice, the cMyBP-C protein can be cleaved at the protease recognition site, and the N-Terminus of cMyBP-C can be removed while the C-terminus remains anchored to the thick filament. A new peptide featuring the SpyCatcher sequence can be covalently bonded to the remaining portion of cMyBP-C, thereby creating a modified cMyBP-C protein. The methods and compositions of the present invention allow for the reconstitution of full-length cMyBP-C at the precise position of native cMyBP-C in the sarcomere and allow for a variety of modifications to be introduced to cMyBP-C in situ.

The invention belongs to the technical field of animal bacteriology and zoonotic disease detection, and in particular relates to an ELISA kit for detecting antibodies to toxin-producing Pasteurella multocida in pigs and its use in preventing and treating progressive atrophic rhinitis (progressive atrophic rhinitis, PAR). The kit includes a box body, a microtiter plate coated with the purified rPMT-C protein at the C' end of the toxA gene expressed as an antigen, negative and positive standard serum, rabbit anti-pig IgG enzyme-labeled secondary antibody, sample dilution Solution, substrate chromogenic solution A, substrate chromogenic solution B, stop solution and washing solution. Also disclosed is the preparation of a recombinant Escherichia coli BL21 / pET28b-C2115 (preservation number: CCTCC NO: M207012) expressing the rPMT-C protein at the C' end of the toxA gene of Pasteurella multocida toxA and the preparation of the rPMT-C protein expression and purification methods. The kit of the invention has the advantages of simple operation, fast and accurate diagnosis, low cost, etc., is suitable for large-scale clinical serological investigation of T+Pm, and can provide technical support for the purification of PAR in pigs.

The invention discloses a recombined human cystatin-C protein with natural activity and a preparation method thereof. According to the preparation method, lots of stable recombined human cystatin-C proteins are expressed and purified by employing a gene engineering technique, and the recombined human cystatin-C proteins are cut by utilizing the protease, so that the recombined human cystatin-C protein has high natural activity. The recombined human cystatin-C protein can be used for immune preparation of monoclonal antibodies and multi-antibody blood serum, and excellent raw materials are provided for preparing stable cystatin-C detection agents and quality control products thereof.

The invention provides an immunogenic cry1C recombinant protein, which relates to the technical field of genetic engineering, and its amino acid sequence is shown in SEQ ID No.1. The amino acid sequence encoding the cry1C recombinant protein is shorter than the amino acid sequence of the full-length cry1C protein, and the cry1C recombinant protein can immunoreact with the cry1C antibody, and can be used to rapidly and efficiently prepare the cry1C antibody. The present invention also provides a nucleic acid encoding the above immunogenic cry1C recombinant protein, a pair of primers capable of amplifying or detecting the nucleic acid molecule, a vector and a host cell including the nucleic acid molecule, and in addition, the present invention also provides a cry1C Antibody and preparation method thereof, the preparation method can obtain cry1C antibody rapidly and efficiently.

The invention discloses an application of a beauveria bassiana analogue as a small molecular agonist of APC / C. The invention discloses the function of activating APC / C of the beauveria bassiana analogue with the natural source as shown in the formula I for the first time, and the beauveria bassiana analogue is a powerful agonist of a late-stage promoter compound (APC / C-Cdh1) or a late-stage promoter compound (APC / C-Cdc20). As a small molecular agonist of APC / C, the compound has important application value in the research fields of cell physiology change caused by APC / C protein activity disorder, targeted activation of APC / C to control cell proliferation disorder diseases and the like.

The invention relates to a colorectal cancer diagnostic marker, a colorectal cancer detection product and an application thereof. The colorectal cancer diagnostic marker includes multiple secreted proteins, and the multiple secreted proteins include one or two of S100A9 protein and tenascin-c protein, and CEA protein. With the characteristics of high sensitivity and strong specificity, the area under the ROC curve of the diagnostic model is 0.902, and the reliability of the diagnostic result is much higher than that of a single protein marker, which is of great significance for the diagnosis and treatment of colorectal cancer. The colorectal cancer detection product includes the above-mentioned colorectal diagnostic markers. The present invention also proposes the application of colorectal diagnostic markers in the preparation of products for auxiliary diagnosis of colorectal cancer.

Methods and means are provided to produce positively charged oligosaccharides in the plant cell wall by introducing into said plant cell a Nodulation C protein fused to a heterologous Golgi signal anchor sequence.